These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 10037184

  • 1. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC.
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [Abstract] [Full Text] [Related]

  • 2. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
    Zhang L, Hung MC.
    Oncogene; 1996 Feb 01; 12(3):571-6. PubMed ID: 8637714
    [Abstract] [Full Text] [Related]

  • 3. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
    Zhang L, Chang CJ, Bacus SS, Hung MC.
    Cancer Res; 1995 Sep 01; 55(17):3890-6. PubMed ID: 7543819
    [Abstract] [Full Text] [Related]

  • 4. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 5. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC.
    Clin Cancer Res; 2000 Jan 06; 6(1):250-9. PubMed ID: 10656456
    [Abstract] [Full Text] [Related]

  • 6. Basic science of HER-2/neu: a review.
    Hung MC, Lau YK.
    Semin Oncol; 1999 Aug 06; 26(4 Suppl 12):51-9. PubMed ID: 10482194
    [Abstract] [Full Text] [Related]

  • 7. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.
    J Surg Res; 2006 May 15; 132(2):208-13. PubMed ID: 16580691
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ.
    Oncogene; 1997 Jul 31; 15(5):537-47. PubMed ID: 9247307
    [Abstract] [Full Text] [Related]

  • 10. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ.
    Cancer Res; 1999 Mar 15; 59(6):1347-55. PubMed ID: 10096569
    [Abstract] [Full Text] [Related]

  • 11. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
    Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC.
    Oncogene; 1998 Jun 04; 16(22):2855-63. PubMed ID: 9671406
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
    Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'reilly MS, Fidler IJ, Herbst RS.
    Clin Cancer Res; 2004 Dec 15; 10(24):8613-9. PubMed ID: 15623645
    [Abstract] [Full Text] [Related]

  • 13. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB.
    Int J Pharm; 2007 Aug 16; 341(1-2):221-9. PubMed ID: 17499461
    [Abstract] [Full Text] [Related]

  • 14. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T, Luoh SW.
    Carcinogenesis; 2008 Mar 16; 29(3):473-9. PubMed ID: 17916906
    [Abstract] [Full Text] [Related]

  • 15. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
    Zhu XF, Liu ZC, Xie BF, Cai LL, Yang DJ.
    Ai Zheng; 2003 Aug 16; 22(8):790-4. PubMed ID: 12917021
    [Abstract] [Full Text] [Related]

  • 16. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A.
    Oncol Rep; 2007 Feb 16; 17(2):465-9. PubMed ID: 17203189
    [Abstract] [Full Text] [Related]

  • 17. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D, Williams JI, Pietras RJ.
    Oncogene; 2002 Apr 25; 21(18):2805-14. PubMed ID: 11973639
    [Abstract] [Full Text] [Related]

  • 18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 19. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.
    Hong RL, Spohn WH, Hung MC.
    Clin Cancer Res; 1999 Jul 29; 5(7):1884-91. PubMed ID: 10430096
    [Abstract] [Full Text] [Related]

  • 20. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H, Qin H, Zhang Y.
    Zhonghua Zhong Liu Za Zhi; 2000 Sep 29; 22(5):370-3. PubMed ID: 11778270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.